About Us

Neurala Biosciences is an Australian clinical-stage biotechnology company developing second-generation psychedelic neuromedicines for mental health and addiction. Emerging from over a decade of research at the University of Melbourne, the company combines precision formulation design with advanced pharmaceutical science to deliver differentiated, IP-protected therapies. Neurala's leadership team brings deep expertise across psychedelic therapeutics, CNS drug development, medicines regulation, and commercialisation. The company has secured $4.5 million in seed funding from Tin Alley Ventures and Genesis Pre-Seed Fund, plus multiple non-dilutive grants, supporting advancement of its lead candidates NBX-100 and NBX-200 toward Phase 2 efficacy studies.

Our Story

Neurala Biosciences was founded in 2022 to translate established DMT-harmala pharmacology into a second-generation platform of precision-engineered neuromedicines, intended to deliver transformative treatments for mental health and addictive disorders.

Our origins lie in a decade of pioneering research on DMT and harmala alkaloid therapeutics, including leading the world’s largest study investigating the therapeutic profile and safety of ayahuasca.

Building on this foundation, we commenced a program of intensive pharmaceutical research and development, leading to the world’s first Phase 1 clinical study of a fully standardised DMT and multi-harmala drug product, with results published in Scientific Reports in 2025.

With multiple patents submitted, a clear regulatory pathway, VC-backed investment, and non-dilutive government funding, we are positioned at the forefront of a revolution in mental health treatment.

Neurala is associated with the not-for-profit Psychae Institute, which holds foundational equity in the company. Psychae Institute contributes towards reciprocity and culturally informed approaches to psychedelic medicines development.